🏆 Deal of the Week · CW 22/2025
GlycoEra raised USD 130 million in a Series B round; the company's valuation was not disclosed. The round was backed by a syndicate of eleven investors spanning dedicated biotech funds, corporate venture arms, and sovereign capital. The financing will advance GlycoEra's targeted autoimmune therapy pipeline.
GlycoEra — key deal facts
| Company | GlycoEra |
| Founded | 2020 |
| Headquarters | Wädenswil, Switzerland |
| Amount raised | USD 130m |
| Valuation | Valuation Remains Undisclosed |
| Round | Series B |
| Investors | 5AM Ventures, Agent Capital, Bristol-Myers Squibb, Catalio Capital Management, LifeArc Ventures, MP Healthcare Venture Management, Novo Holdings, Qatar Investment Authority, Roche Venture Fund, Sixty Degree Capital, Sofinnova Partners |
| Sectors | Biotechnology |
Who invested in GlycoEra?
The Series B was supported by 5AM Ventures, Agent Capital, Bristol-Myers Squibb, Catalio Capital Management, LifeArc Ventures, MP Healthcare Venture Management, Novo Holdings, Qatar Investment Authority, Roche Venture Fund, Sixty Degree Capital, and Sofinnova Partners. The investor base is notably broad, combining specialist life-science venture funds with two strategic corporate investors — Bristol-Myers Squibb and Roche Venture Fund — alongside sovereign capital from the Qatar Investment Authority. That mix of financial, strategic, and government-backed capital signals strong cross-sector conviction in GlycoEra's platform.
What does GlycoEra do?
GlycoEra is a biotechnology company founded in January 2021 as a spinoff and headquartered in Wädenswil, Switzerland, with an additional presence in Newton, Massachusetts. The company engineers bispecific biologics — its proprietary G-LyTAC molecules — that selectively degrade extracellular, disease-causing proteins such as pathogenic IgG4 antibodies. Its lead asset, GE8820, targets immune disorders and is developed on the CustomGlycan platform, which enables precision engineering of novel biologics for immunology and adjacent therapeutic areas. The company is led by president and CEO Ganesh Kaundinya, alongside co-founders Dominique Sirena, Manuela Mally, and Tanmoy Ganguly.
GlycoEra valuation & multiples
No existing multiples analysis was provided for this deal. Comparable private-stage biotechnology transactions are typically assessed on pipeline-risk-adjusted revenue and EBITDA metrics; published EV/Sales and EV/EBITDA ranges for the sector are covered on the Venionaire DealMatrix biotechnology sector multiples pages, where readers can benchmark GlycoEra's round against peer financings.
Explore the benchmarks: Series B.
Frequently asked questions
How much did GlycoEra raise in its Series B?
GlycoEra raised USD 130 million in its Series B round, announced in 2025 (KW 22/2025).
What is GlycoEra's valuation?
GlycoEra's valuation was not disclosed in connection with this Series B financing.
Who invested in GlycoEra?
The Series B investors include 5AM Ventures, Agent Capital, Bristol-Myers Squibb, Catalio Capital Management, LifeArc Ventures, MP Healthcare Venture Management, Novo Holdings, Qatar Investment Authority, Roche Venture Fund, Sixty Degree Capital, and Sofinnova Partners.
When was GlycoEra founded and where is it based?
GlycoEra was founded in January 2021 and is headquartered in Wädenswil, Switzerland, with an additional office in Newton, Massachusetts.
Source: original announcement — read the full report.